Provenge Extends Survival of mCRPC Patients By Up to 4 Years, Data Show

Provenge Extends Survival of mCRPC Patients By Up to 4 Years, Data Show
Treatment with the immunotherapy Provenge (sipuleucel-T) in a real-world setting is showing  similar safety and efficacy in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) as in clinical trials, a study shows. The observational registry study — called PROCEED (NCT01306890) — conducted at urology and medical oncology clinics showed that men with lower prostate specific antigen (PSA) levels at baseline lived nearly four years after receiving Provenge. “The median survival of four years following treatment with PROVENGE is meaningful,” Celestia S. Higano, MD, FACP, lead author of the PROCEED analysis, said in a press release. The study, “Real-world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer,” was published in the journal Cancer. Provenge, marketed by Dendreon Pharmaceuticals, is an immunotherapy that uses a patient’s own immune cells to fight prostate cancer. In it, a fraction of
Subscribe or to access all post and page content.